CXCL17 is a C-X-C motif chemokine with selective expression in mucosal tissues, airways, and epithelial barriers that functions primarily as a chemoattractant for immune cells 1. The chemokine signals through GPR25 (also known as CXCR8) on lymphocytes and through GPR35 on macrophages and myeloid-derived suppressor cells (MDSCs) 213. CXCL17 exhibits higher chemoattractant potency on monocytes and macrophages and recruits CCR10+ immune cells to mucosal tissues 1. Mechanistically, CXCL17 expression is upregulated by the YAP/TEAD1 signaling pathway in endothelial cells during hypoxic stress, such as liver ischemia-reperfusion injury 3. The chemokine plays dual roles in disease: protective functions include modulating immune responses against mycotoxins, supporting antiviral immunity, and recruiting regulatory T cells to non-intestinal mucosae and the CNS 425; conversely, elevated CXCL17 is associated with disease progression in pulmonary fibrosis, asthma, and certain cancers 5. CXCL17's strategic positioning at barrier epithelia and its immunomodulatory properties suggest therapeutic potential for managing mucosal inflammation, ischemia-reperfusion injury, and autoimmune conditions 532.